CSIMarket
 

Ispecimen inc   (ISPC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Ispecimen Inc 's Working Capital Per Sales

ISPC's Working Capital and Revenue growth



ISPC Working Capital Per Revenue (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Working Capital Change -85.6 % -73.79 % -67.19 % -56.4 % -49.43 %
Y / Y Revenue Change -13.05 % 7.52 % -30.51 % 17.13 % -
Working Capital Per Revenue 0.71 1.01 1.42 1.71 2.16
Total Ranking # 1789 # 2674 # 2913 # 2999 # 3492
Seq. Working Capital Change -60.47 % -31.88 % -32.79 % -20.41 % -28.07 %
Seq. Revenue Change -7.3 % 70.92 % -44.91 % -0.38 % 14.64 %





Comment on ISPC's Working Capital Per Revenue in the fourth quarter 2023
Ispecimen Inc 's Working Capital Per Revenue in the Q4 2023 sequentially fell to 0.71 a new company low. Due to decrease of revenue year on year in the fourth quarter 2023 by -13.05%.

Within Healthcare sector 34 other companies have achieved lower Working Capital Per Revenue during the Q4 2023. While Ispecimen Inc Working Capital Per Revenue overall ranking has impoved so far in the Q4 2023 to 1789, from total ranking in the third quarter 2023 at 2674.
Working Capital Per Revenue Ranking
Within: No.
Industry # 4
Sector # 35
S&P 500 # 1789


Working Capital Per Revenue Statistics
High Average Low
14.44
5.24
0.71
(Sep 30 2022)   (Dec 31 2023)



Financial Statements
Ispecimen Inc 's Working Capital $ 2 Millions Visit ISPC's Balance sheet
Ispecimen Inc 's Revenues $ 3 Millions Visit ISPC's Income Statement
Where are ISPC's Sales coming from? Visit ISPC's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Dec 31 2023, within Healthcare Sector Working Capital Per Revenue
Guardant Health Inc   1.93 
Ocular Therapeutix Inc   1.92 
Procept Biorobotics Corporation  1.91 
Entrada Therapeutics Inc   1.90 
Arrowhead Pharmaceuticals Inc   1.89 
Cytek Biosciences Inc   1.87 
Utah Medical Products Inc  1.82 
Sophia Genetics Sa  1.82 
Novocure Limited  1.77 
Indivior Plc  1.74 
The Beauty Health Company  1.61 
Inmode Ltd   1.59 
Biomerica Inc   1.56 
Neuroone Medical Technologies Corporation  1.52 
Argenx se  1.48 
Inmed Pharmaceuticals Inc   1.45 
Clearpoint Neuro Inc   1.41 
Twist Bioscience Corporation  1.40 
Intra cellular Therapies Inc   1.28 
Urogen Pharma Ltd   1.27 
Casi Pharmaceuticals inc   1.26 
Si bone inc   1.24 
Orthopediatrics Corp  1.23 
Olink Holding Ab publ   1.23 
G1 Therapeutics Inc   1.23 
United Therapeutics Corporation  1.20 
Silk Road Medical Inc   1.19 
Biocryst Pharmaceuticals Inc   1.19 
Revance Therapeutics Inc   1.18 
Beigene ltd   1.18 
Date modified: 2024-03-13T23:05:05+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com